There has been growing criticism of “vaccine inequality” as developing countries struggle to secure supplies while wealthy nations begin inoculating populations.
A lot of people are surviving cancer because new treatments are so effective. But there's one thing that stands in the way for many people, and that's having the money to pay for the drugs to fight their cancer.
Georgia Tech researchers received a grant from the Food and Drug Administration to develop a way to continuously manufacture common antibiotics like amoxicillin. This process could help reduce costs and avoid shortages.
Macroeconomic pressures have hit the R&D returns of life sciences firms.